Pharsight

1. List of Trulance drug patents

Application	Filing Date	Opposition Party	Legal Status
EP02721604A	2010-04-22	Hill, Christopher Michael	Patent maintained as amended
EP02721604A	2010-04-22	CombiMab, Inc.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US7041786	October, 2022	Instituted	Salix Pharmaceuticals, Inc.	MSN Laboratories Private Ltd.
US9610321	June, 2022	Institution Denied	Bausch Health Ireland Limited et al.	Mylan Pharmaceuticals Inc. et al.
US9616097	June, 2022	Institution Denied	Bausch Health Ireland Limited et al.	Mylan Pharmaceuticals Inc. et al.
US9919024	June, 2022	Terminated-Denied	Bausch Health Ireland Limited	Mylan Pharmaceuticals Inc.
US9925231	June, 2022	Institution Denied	Bausch Health Ireland Limited et al.	Mylan Pharmaceuticals Inc. et al.
US7041786	March, 2022	Trial Instituted	Bausch Health Ireland Limited et al.	Mylan Pharmaceuticals Inc. et al.

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897	SALIX	Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis	Jun, 2022 (11 months ago)
US7041786	SALIX	Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis	Jan, 2028 (4 years from now)
US10011637	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Jun, 2034 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637451	SALIX	Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis	Mar, 2022 (1 year, 2 months ago)
US9610321	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Sep, 2031 (8 years from now)
US9919024	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Sep, 2031 (8 years from now)
US9925231	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Sep, 2031 (8 years from now)
US11319346	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Mar, 2032 (8 years from now)
US9616097	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Aug, 2032 (9 years from now)
US11142549	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Jun, 2034 (10 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 19, 2022

NCE-1 date: 2021-01-19

Market Authorisation Date: 19 January, 2017

Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Chronic idiopathic constipation; Irritable bowel syndrome with constipation

Dosage: TABLET;ORAL